Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B

IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Journal of Viral Hepatitis Pub Date : 2025-03-15 DOI:10.1111/jvh.70019
Huiqing Liang, Xiaoting Zheng, Yaoyu Liu, Qianguo Mao, Chuncheng Wu, Li Lin, Zhizhen Huang, Yue Chen, Manying Zhang, Luyun Zhang, Jia Min, Min Hu, Huiying Luo, Shaodong Chen, Xiaohong Gu
{"title":"Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B","authors":"Huiqing Liang,&nbsp;Xiaoting Zheng,&nbsp;Yaoyu Liu,&nbsp;Qianguo Mao,&nbsp;Chuncheng Wu,&nbsp;Li Lin,&nbsp;Zhizhen Huang,&nbsp;Yue Chen,&nbsp;Manying Zhang,&nbsp;Luyun Zhang,&nbsp;Jia Min,&nbsp;Min Hu,&nbsp;Huiying Luo,&nbsp;Shaodong Chen,&nbsp;Xiaohong Gu","doi":"10.1111/jvh.70019","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Oral nucleotide analogues (NAs) and peginterferon-α injections are commonly used for the treatment of patients with chronic hepatitis B (CHB). This study aims to evaluate the effects of different antiviral therapies on the degree of liver inflammation and fibrosis in CHB patients. This was a retrospective cohort study. A total of 101 CHB patients were admitted to the Liver Center of Xiamen Hospital of Traditional Chinese Medicine from 2017 to 2021 and were divided into three groups for different antiviral treatments: NAs therapy group (<i>n</i> = 36), peginterferon-α therapy group (<i>n</i> = 38) and nonantiviral therapy group (<i>n</i> = 27). The differences in degrees of liver inflammation and liver fibrosis between two histopathologic biopsies before and after treatment were analysed and compared to evaluate the efficacy of different treatments. The degrees of liver inflammation and liver fibrosis were improved after NAs or peginterferon-α therapy. In terms of improving the degree of liver inflammation, peginterferon-α therapy (74%) and NAs therapy (44%) were better than nonantiviral therapy (11%, <i>p</i> &lt; 0.05), although no significant difference was shown between peginterferon-α therapy and NAs therapy (<i>p</i> = 0.974). For liver fibrosis improvement, peginterferon-α therapy showed significantly better efficacy than NAs therapy (68% vs. 33%, <i>p</i> = 0.044), while NAs therapy was better than nonantiviral therapy (33% vs. 11%, <i>p</i> = 0.028). Peginterferon-α and NAs can significantly improve the degree of liver inflammation and liver fibrosis in CHB patients. Peginterferon-α is superior to NAs in delaying and reversing liver fibrosis. This study provides a new basis for peginterferon-α therapy to prevent progression of fibrosis in CHB patients.</p>\n </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Viral Hepatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvh.70019","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Oral nucleotide analogues (NAs) and peginterferon-α injections are commonly used for the treatment of patients with chronic hepatitis B (CHB). This study aims to evaluate the effects of different antiviral therapies on the degree of liver inflammation and fibrosis in CHB patients. This was a retrospective cohort study. A total of 101 CHB patients were admitted to the Liver Center of Xiamen Hospital of Traditional Chinese Medicine from 2017 to 2021 and were divided into three groups for different antiviral treatments: NAs therapy group (n = 36), peginterferon-α therapy group (n = 38) and nonantiviral therapy group (n = 27). The differences in degrees of liver inflammation and liver fibrosis between two histopathologic biopsies before and after treatment were analysed and compared to evaluate the efficacy of different treatments. The degrees of liver inflammation and liver fibrosis were improved after NAs or peginterferon-α therapy. In terms of improving the degree of liver inflammation, peginterferon-α therapy (74%) and NAs therapy (44%) were better than nonantiviral therapy (11%, p < 0.05), although no significant difference was shown between peginterferon-α therapy and NAs therapy (p = 0.974). For liver fibrosis improvement, peginterferon-α therapy showed significantly better efficacy than NAs therapy (68% vs. 33%, p = 0.044), while NAs therapy was better than nonantiviral therapy (33% vs. 11%, p = 0.028). Peginterferon-α and NAs can significantly improve the degree of liver inflammation and liver fibrosis in CHB patients. Peginterferon-α is superior to NAs in delaying and reversing liver fibrosis. This study provides a new basis for peginterferon-α therapy to prevent progression of fibrosis in CHB patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服核苷酸类似物(NAs)和注射peginterferon-α是治疗慢性乙型肝炎(CHB)患者的常用方法。本研究旨在评估不同抗病毒疗法对慢性乙型肝炎患者肝脏炎症和纤维化程度的影响。这是一项回顾性队列研究。2017年至2021年,厦门市中医院肝病中心共收治101例CHB患者,并将其分为三组,接受不同的抗病毒治疗:NAs治疗组(n=36)、peginterferon-α治疗组(n=38)和非抗病毒治疗组(n=27)。分析并比较治疗前后两次组织病理活检的肝脏炎症和肝纤维化程度的差异,以评估不同疗法的疗效。经过NAs或聚乙二醇干扰素α治疗后,肝脏炎症和肝纤维化程度均有所改善。在改善肝脏炎症程度方面,peginterferon-α疗法(74%)和NAs疗法(44%)优于非抗病毒疗法(11%,p < 0.05),但peginterferon-α疗法和NAs疗法之间无显著差异(p = 0.974)。在改善肝纤维化方面,peginterferon-α疗法的疗效明显优于NAs疗法(68% vs. 33%,p = 0.044),而NAs疗法优于非抗病毒疗法(33% vs. 11%,p = 0.028)。Peginterferon-α和NAs能明显改善慢性阻塞性肺病患者的肝脏炎症和肝纤维化程度。在延缓和逆转肝纤维化方面,Peginterferon-α优于NAs。这项研究为peginterferon-α疗法预防CHB患者肝纤维化的进展提供了新的依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Viral Hepatitis
Journal of Viral Hepatitis 医学-病毒学
CiteScore
6.00
自引率
8.00%
发文量
138
审稿时长
1.5 months
期刊介绍: The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working in the field, thereby bringing together in a single journal the important issues in this expanding speciality. The Journal of Viral Hepatitis is a monthly journal, publishing reviews, original work (full papers) and short rapid communications in the area of viral hepatitis. It brings together in a single journal important issues in this rapidly expanding speciality including articles from: virologists; epidemiologists; clinicians; pathologists; specialists in transfusion medicine.
期刊最新文献
Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B Impact of HBV Infection in Couples on In Vitro Fertilisation-Embryo Transfer Outcomes and Clinical Characteristics of Newborns: A Retrospective Study Based on 3900 Infertile Couples Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1